AddedRisk Factors
Our agricultural production and trade flows can be affected by government programs and legislation. Production levels, markets and prices of the commodities we merchandise can be affected by U.S. government programs, which include acreage controls and price support programs administered by the USDA and required levels of ethanol in gasoline through the Renewable Fuel Standards as administered by the EPA. Other examples of government policies that can have an impact on our business include the Inflation Reduction Act, tariffs, taxes, duties, subsidies, import and export restrictions, outright embargoes and price controls on agricultural commodities. Because a portion of our commodity sales are to exporters, the imposition of export restrictions and other foreign countries’ regulations could limit our sales opportunities and create additional credit risk associated with export brokers if shipments are rejected at their destination.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
AddedRisk Factors
Our Company manufactures certain agricultural nutrients and uses potentially hazardous materials. All products containing pesticides, fungicides and herbicides must be registered with the EPA and state regulatory bodies before they can be sold. The inability to obtain or the cancellation of such registrations could have an adverse impact on our business. In the past, regulations governing the use and registration of these materials have required us to adjust the raw material content of our products and make formulation changes. Future regulatory changes may have similar consequences. Regulatory agencies, such as the EPA, may at any time reassess the safety of our products based on new scientific knowledge or other factors. If it were determined that any of our products were no longer considered to be safe, it could result in the amendment or withdrawal of existing approvals, which, in turn, could result in a loss of revenue, cause our inventory to become obsolete or give rise to potential lawsuits against us. Consequently, changes in existing and future government or trade association polices may restrict our ability to do business and have an adverse impact on the Company’s financial results.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
AddedRisk Factors
Varying definitions in regulations create regulatory uncertainty for our Company when adapting to new environmental rules, including changes to EPA requirements.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
AddedRisk Factors
Regulatory bodies may use different definitions for regulated substances, which may result in uncertainty for our Company when adapting to new environmental rules. For example, the EPA defines PFAS as chemicals with two or more fluorinated carbon atoms whereas OECD defines PFAS as containing at least one fluorinated carbon atom. Increased pressure from non-government organizations and public opinion influence policy and regulatory bodies, which may result in frequent changes in federal and state regulations causing disparate standards across jurisdictions. This regulatory uncertainty may cause restrictions or bans on certain products, coupled with increased litigation risks due to opaque compliance requirements, as well as difficulty in long-term planning and investment decisions, which adversely impact product development and reformulation. Furthermore, regulatory uncertainty may increase cash outflows for compliance and securitization of reserves. These effects of regulatory uncertainty could adversely impact our financial results.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
RemovedRisk Factors
Pricing and volumes in our markets are sensitive to a number of industry specific and global issues and events including:
Read it in 10-K Feb 28, 2025 at sec.govopen_in_new
RemovedRisk Factors
•Climate conditions – Our markets are affected by climatic conditions, both chronic and acute, which could adversely impact crop yields, pricing and pest infestations. For example, drought may reduce the need for fungicides, which could result in fewer sales and greater unsold inventories in the market, whereas excessive rain could lead to increased plant disease or weed growth requiring growers to purchase and use more pesticides. Drought and/or increased temperatures may change insect pest pressures, requiring growers to use more, less, or different insecticides. Natural disasters can impact production at our facilities in various parts of the world. The nature of these events makes them difficult to predict.
Read it in 10-K Feb 28, 2025 at sec.govopen_in_new
RemovedRisk Factors
•Climate change and land use impacts – Climate change may impact markets in which we sell our products, where, for example, a prolonged drought may result in decreased demand for our products. The more gradual effects of persistent temperature change in geographies with significant agricultural lands may result in changes in lands suitable for agriculture or changes in the mix of crops suitable for cultivation and the pests that may be present in such geographies. These shifts in pests may become more rapid and persistent with rising temperatures and increasing GHG levels. For example, prolonged increase in average temperature may make northern lands suitable for growing crops not grown historically in such climates, leading growers to shift crop type. It may also result in new or different weed, plant disease or insect pressures and such changes could impact the mix of crop protection products growers would purchase and, depending on the local market and our product offering, may be adverse for us. Growers may need to implement regenerative practices and shift to more climate-adaptive products as climate change impacts global crop yields and shifts harvestable regions and pest pressures.
Read it in 10-K Feb 28, 2025 at sec.govopen_in_new
RemovedRisk Factors
•Litigation and environmental risks – Current reserves relating to our ongoing litigation and environmental liabilities may ultimately prove to be inadequate, which may have a material adverse impact on our results of operations. Products reviewed by regulators and labeled safe for use may still be challenged by others which could result in lawsuits or claims.
Read it in 10-K Feb 28, 2025 at sec.govopen_in_new
RemovedRisk Factors
•Technological and new product discovery/development – Our ability to compete successfully depends in part upon our ability to maintain a superior technological capability and to continue to identify, develop and commercialize new and
Read it in 10-K Feb 28, 2025 at sec.govopen_in_new
RemovedRisk Factors
•Foreign exchange rate risks – We are an international company operating in many countries around the world, and thus face foreign exchange rate risks in the normal course of business. We are particularly sensitive to the movements of the Brazilian real, Chinese yuan, Indian rupee, Euro, Mexican peso and Argentine peso. While we engage in hedging and other strategies to mitigate these risks, unexpected severe changes in foreign exchange may create risks that could materially and adversely affect our expected performance.
Read it in 10-K Feb 28, 2025 at sec.govopen_in_new
RemovedRisk Factors
•Uncertain recoverability of investments in long-lived assets – We have significant investments in long-lived assets and continually review the carrying value of these assets for recoverability in light of changing market conditions and alternative product sourcing opportunities. We may recognize future impairments of long-lived assets, which could adversely affect our results of operations.
Read it in 10-K Feb 28, 2025 at sec.govopen_in_new
RemovedRisk Factors
•Compliance with laws and regulations – The global regulatory environment is becoming increasingly complex and requires more resources to effectively manage, which may increase the potential for misunderstanding or misapplication of regulatory standards.
Read it in 10-K Feb 28, 2025 at sec.govopen_in_new
RemovedRisk Factors
•Restructuring – In 2023, we implemented a global restructuring plan, which is referred to as “Project Focus,” designed to right-size our cost base and optimize our footprint and organizational structure with a focus on driving significant cost improvement and productivity in light of the precipitous drop in demand across the crop protection industry in 2023. While we have realized substantially all the expected synergies from the program, we may need to implement additional activities under the restructuring program to offset market headwinds and other risks should they negatively impact our results of operations. In addition, our failure to effectively manage organizational changes as part of the restructuring program may lead to increased attrition and harm our ability to attract and retain key talent.
Read it in 10-K Feb 28, 2025 at sec.govopen_in_new
RewordedRisk Factors
An abrupt and widespread shift in purchasing behaviors (e.g., the current inventory destocking phenomenon) by channel partners and end use end-use customers has has, in the past, negatively and may continue to materially impacted and may, in the future, negatively and materially impact the Company’s volumes across important markets, which has adversely affected markets and may continue to adversely affect our results of operations.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
RewordedRisk Factors
Such adverse effects could include include, but are not be limited to to, materially reduced volumes purchased by customers, customers resulting in not only reduced sales, but also the Company bearing sales as well as higher volumes of unsold product inventory, inventory and excess raw materials, materials and correspondingly increased carrying costs.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
RewordedRisk Factors
In If we are not able to maintain compliance with the covenants under our debt agreements, and in the event of a default in this credit facility our Revolving Credit Facility or any of our senior notes, we could be required to immediately repay all outstanding borrowings and make cash deposits as collateral for all obligations the facility supports, which we may not be able to do.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
RewordedRisk Factors
We In addition to the now-expired composition of matter patents for these diamide active ingredients, we also have additional patents regarding the production of these diamide active ingredients and chemical intermediates involved in such production, which are expiring expired in many major markets in December 2025.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
RewordedRisk Factors
We believe that our cash from operations and available borrowings under our revolving credit facility the Fifth Amended and Restated Credit Agreement, dated as of June 17, 2022 (the "Revolving Credit Facility"), will be sufficient to meet these needs in the foreseeable future.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
RewordedRisk Factors
Accordingly, Because most of our products are commodities, increases in such commodity prices prices, including chemical raw material or energy commodity pricing, may negatively affect our financial results.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
RewordedRisk Factors
In recent years, we have seen some logistics challenges, pointed supply chain shortages, and increased cost of goods due to disruptions in energy markets (such as that caused by the Russian war on Ukraine), markets, inflation and tariffs (such as those discussed above). tariffs.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
RewordedRisk Factors
These potential Our manufacturing processes and those of our contract manufacturers are subject to hazards inherent in chemical manufacturing, which include explosions, fires, mechanical failure, unscheduled downtimes, supplier disruptions, labor shortages or other labor difficulties, information technology systems outages, disruption in our supply chain or manufacturing and distribution operations, transportation interruptions, chemical spills, discharges or releases of toxic or hazardous substances or gases, shipment of contaminated or off-specification product to customers, storage tank leaks, other environmental risks, cyberattacks, or other sudden disruption in business operations beyond our control as a result of events such as acts of sabotage, terrorism or war, civil or political unrest, severe weather and natural disasters, large scale power outages and public health epidemics and pandemics.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
RewordedRisk Factors
All The nature of these items events makes them difficult to predict and may have result in significant costs or capital expenditures.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
RewordedRisk Factors
There is considerable uncertainty surrounding the trade relationship between the U.S. and trading partners — e.g., the recently announced 10% tariff tariffs on goods coming into the U.S. from China, the recent announcement of reciprocal tariffs on goods imported into the U.S. to match tariffs imposed by other nations on goods imported from the U.S., and China’s recently announced tariffs on imports of certain U.S. goods.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
RewordedRisk Factors
Some of these the hazards inherent in chemical manufacturing (e.g., spills, explosions, fires) may cause severe damage to or destruction of property and equipment or personal injury and loss of life and may result in suspension of operations or the shutdown of affected facilities.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
RewordedRisk Factors
In addition, climate change may result in changes to the governmental policy around greenhouse gases, gases and other environmental and sustainability‑related matters, including emission caps, trade regulations and other mechanisms to promote reduction of carbon emissions.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
Quiet changesRisk Factors
Other However, third parties may seek to enter markets with infringing products or may find alternative production methods that avoid infringement.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
Quiet changesRisk Factors
Significant effort will likely be is required to ensure that the right mix of resources are trained, engaged and focused on achieving business objectives while adhering to our core values of safety, ethics and compliance.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
Quiet changesRisk Factors
There can be no assurances that we would be able to obtain equity or debt financing on terms we deem acceptable, and it is possible that the cost of any financings could increase significantly, increase, thereby increasing our expenses and decreasing our net income.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
Quiet changesRisk Factors
If we are unable to generate sufficient cash flow or raise adequate external financing, including as a result of significant disruptions in the global credit markets, we could be forced to restrict our operations and growth opportunities, which could adversely affect our operating results.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
AddedMD&A
In July 2025, the Board of Directors approved a plan to divest the Company’s commercial business in India in response to ongoing commercial challenges in the country. FMC plans to continue to actively participate in the India market through a supply agreement with the eventual buyer of the business for its patented and data-protected portfolio, ranging from new diamide technologies to active ingredients and biologicals. The Company will continue its active ingredients manufacturing operations in India. The sale process is underway and is expected to conclude in 2026; and, therefore, the assets related to this business are classified as held for sale beginning in the third quarter of 2025. However, there is no assurance that we will be able to complete the divestment in the expected timeline and on favorable terms, or that we will be able to successfully enter into a supply agreement with the buyer. Although the business does not qualify for recognition as discontinued operations and will continue to be presented in the Company's reported results until a transaction is completed, we believe excluding India's operating results from our non-GAAP measures during the held for sale period, beginning with the third quarter of 2025, provides management and investors with useful supplemental information regarding our ongoing financial performance. In preparation for the sale, we took a series of target actions to optimize the business for transfer and reflect its fair value.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
AddedMD&A
The assets associated with the India commercial business held a carrying value of approximately $960 million at June 30, 2025. We evaluated the fair value of the assets associated with the business and determined the estimated fair value less costs to sell to be $450 million. Accordingly, we recorded $522 million of charges and write-downs in 2025 as a result of one-time commercial actions to prepare the India business for sale and an asset impairment charge in accordance with the held-for-sale accounting standards. This adjustment was reflected across multiple income statement line items as presented in the table below.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
AddedMD&A
Twelve Months Ended Affected Line Item in the Consolidated Statements of Income (Loss) December 31, (in Millions) 2025 2024 Operating results, substantially one-time commercial actions $ 319.8 $ Revenue, Cost of sales and services, and Selling, general and administrative expenses Asset impairment 194.8 — Restructuring and other charges (income) Third party provider costs 7.1 — Restructuring and other charges (income) India held for sale business $ 521.7 $
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
AddedMD&A
•Operating results, substantially pre-sale commercial adjustments ($320 million): These one-time actions commenced during the period included product returns and pricing changes designed to (1) accelerate receivables collection, (2) optimize the working capital mix of receivables and inventory, and (3) address contemporaneous changes in local indirect taxation. These adjustments impacted both the Revenue and Cost of sales and services line items on the consolidated statement of income (loss), resulting in revenue charges for the India business in the third quarter of 2025. These actions were taken in both collaboration with and in anticipation of customer behavior stemming from known indirect tax implications and broader market dynamics. These steps will help mitigate collection and local tax risks and position the business for a stronger sale outcome. The $320 million is made up of revenue charges of $422 million, a credit to cost of sales of $128 million and SG&A charges of $26 million.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
AddedMD&A
•Asset impairment ($195 million): Following the commercial adjustments, we evaluated the remaining carrying value of the net assets associated with the business. The difference between the adjusted carrying value and the estimated fair value, less costs to sell, was recorded as an asset impairment, reflected within the Restructuring and Other Charges line item on the consolidated statement of income (loss).
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
AddedMD&A
Balance sheet impact - The combination of commercial adjustments and impairment resulted in a write-down of the net assets identified as held for sale to $450 million, as presented on the consolidated balance sheet as of December 31, 2025.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
AddedMD&A
•In December 2025, the Board of Directors approved management’s comprehensive plan, referred to as Project Foundation, to further optimize FMC’s cost structure and organizational operations. A key component of this initiative is the Manufacturing Restructuring Program, which focuses on redesigning FMC’s manufacturing footprint and includes exiting certain high-cost active ingredient and formulation plants and transitioning production to lower-cost sources. These actions are intended to create a cost-competitive structure that enables FMC’s products to better compete with generics while fully leveraging its innovative technology portfolio. In addition, we are implementing cost-reduction initiatives in Asia to reflect the smaller scale of the region’s business following the planned sale of the India commercial operations. We intend to continue to right-size our cost base and optimize the overall organizational structure, with a sustained focus on driving cost improvements and productivity amid ongoing challenges. However, these actions may take longer than expected to implement, may result in higher-than-anticipated costs or operational disruptions, and may not achieve the expected efficiencies, cost savings or strategic objectives. During the twelve months ended December 31, 2025, we incurred non-cash asset write-off and accelerated depreciation costs of $155.7 million primarily associated with the planned exit of certain production activities, other miscellaneous charges, including professional service provider costs, of $14.5 million and severance and employee separation costs of $1.8 million in connection with Project Foundation.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
AddedMD&A
•Net loss attributable to FMC stockholders of $2,238.9 million decreased $2,580.0 million compared to net income attributable to FMC stockholders of $341.1 million in the prior year primarily driven by a significant increase in restructuring and other charges recorded during the period. As a result of the significant decrease in our stock price during the fourth quarter of 2025, we performed a test of our goodwill and other intangible assets for impairment in connection with the preparation of our financial statements for the year ending December 31, 2025. We recorded a $1,356.2 million write-off of our remaining goodwill balance in connection with the impairment test. Additionally, as previously mentioned, we recorded $522 million of charges and write-downs in 2025 as a result of one-time commercial actions to prepare the India commercial business for sale and an asset impairment charge in accordance with the held-for-sale accounting standards. Adjusted after-tax earnings from continuing operations attributable to FMC stockholders of $372.0 million decreased $64.3 million or approximately 15 percent. See the disclosure of our adjusted earnings non-GAAP financial measurement under the section titled "Results of Operations".
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
AddedMD&A
In 2026, we plan to focus on executing our operational priorities, one of which is strengthening the balance sheet by paying down debt through asset sales and licensing agreements, including the previously announced sale of our India commercial business which is classified as held for sale. Our priorities also include improving the competitiveness of the company's legacy core portfolio, managing the post-patent transition for Rynaxypyr® active, and supporting the growth of new active ingredients, such as Isoflex® active, fluindapyr, Dodhylex™ active and rimisoxafen. However, we expect continued pressure on price during the year due to competitive market dynamics for core portfolio products and lower Rynaxypyr® active pricing. We will maintain our focus on reducing costs, which are expected to be lower for the full year despite expected pressure in the first quarter due to the timing of tariffs and manufacturing variances.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
AddedMD&A
Additionally, as announced in February 2026, the Board of Directors has authorized the exploration of strategic options, including but not limited to, the sale of the company. FMC's four new active ingredients, along with its broader development pipeline, are unique and transformative. The company believes there is significant opportunity to enhance shareholder value and ensure the long-term success of our portfolio by accelerating growth and delivering enhanced financial results with additional investment in these technologies. The strategic review is at a preliminary stage, and there can be no assurance that the process will result in any transaction.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
AddedMD&A
(5)Beginning with the third quarter of 2025, the operating results of the India commercial business are excluded from our Adjusted EBITDA during the held for sale period. For the year ended December 31, 2025, we have excluded $521.7 million in charges and write-downs related to the India held for sale business including charges of $319.8 million recognized in connection with one-time commercial actions to position the India business for sale, asset impairment charges of $194.8 million to record the assets held for sale to their estimated fair value less costs to sell, and $7.1 million in third party provider costs incurred in connection with the transaction. The one-time commercial actions to prepare the India business for sale resulted in a decrease to the Revenue and Cost of sales and services line items on the consolidated statement of income (loss) and the impairment charges as well as third party provider costs were recorded to Restructuring and other charges (income) on the consolidated statement of income (loss). Refer to the India Held for Sale Business section for further details.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
AddedMD&A
(1)Represents restructuring and other charges (income), and non-operating pension, postretirement and other charges (income). The year ended December 31, 2025 includes charges incurred in connection with a shutdown of a product line at one of our manufacturing sites as part of Project Focus of $17.3 million, which are recorded to "Cost of Sales and services" on the consolidated statements of income (loss). Charges of $1,758.4 million recorded as "Restructuring and other charges (income)" on the consolidated statements of income (loss) for the year ended December 31, 2025 are also included in the reconciliation above.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
RemovedMD&A
•In response to the unprecedented downturn in the global crop protection market during 2023, we initiated a global restructuring plan, referred to as "Project Focus," in November 2023 designed to right-size our cost base and optimize our footprint and organizational structure with a focus on driving significant cost improvement and productivity. Refer to the section titled "Results of Operations" for further discussion of the program.
Read it in 10-K Feb 28, 2025 at sec.govopen_in_new
RemovedMD&A
We expect 2025 revenue will be in the range of approximately $4.15 billion to $4.35 billion, essentially flat at the midpoint versus 2024 and an increase of 3 percent excluding the impact of approximately $110 million in sales from the prior year due to the divestiture of the GSS business. Volume is expected to improve as increases in growth platforms are expected to more than offset weaker demand in the channel as customers in many countries prioritize holding lower than historical inventory. Price is expected to decline in the mid-single digits almost entirely driven by certain contract adjustments to diamide partners to account for lower manufacturing costs. Foreign currency impacts are expected to be a low-single digit headwind. We expect adjusted EBITDA(1) of $870 million to $950 million, an increase of 1 percent at the midpoint versus 2024 results and up 4 percent after excluding the impact of the loss of approximately $25 million in EBITDA from the prior year due to the divestiture of the GSS business. Favorable costs and a modest volume gain are expected to be mostly offset lower price, foreign currency headwinds, and increases in selling costs as the Company invests in new routes to market. 2025 adjusted earnings are expected to be in the range of $3.26 to $3.70 per diluted share(1), essentially flat at the midpoint versus 2024. The estimate for adjusted earnings excludes any impact from potential share repurchases in 2025. For cash flow outlook, refer to the liquidity and capital resources section below.
Read it in 10-K Feb 28, 2025 at sec.govopen_in_new
RemovedMD&A
(1)Although we provide forecasts for adjusted earnings per diluted share and adjusted EBITDA (Non-GAAP financial measures), we are not able to forecast the most directly comparable measures calculated and presented in accordance with U.S. GAAP. Certain elements of the composition of the U.S. GAAP amounts are not predictable, making it impractical for us to forecast. Such elements include, but are not limited to, restructuring, acquisition charges, and discontinued operations. As a result, no U.S. GAAP outlook is provided.
Read it in 10-K Feb 28, 2025 at sec.govopen_in_new
RemovedMD&A
(1)Represents restructuring and other charges (income), and non-operating pension and postretirement charges (income).
Read it in 10-K Feb 28, 2025 at sec.govopen_in_new
RemovedMD&A
For 2025, full-year revenue is expected to be in the range of approximately $4.15 billion to $4.35 billion, which is essentially flat at the midpoint versus 2024 and an increase of 3 percent excluding the impact of approximately $110 million in sales from the prior year due to the divestiture of the GSS business.
Read it in 10-K Feb 28, 2025 at sec.govopen_in_new
RemovedMD&A
North America: Revenue decreased approximately 16 percent in the year ended December 31, 2023. The significant decrease in volumes period over period was due to the channel destocking by growers and the distribution channel. The decrease in volumes was partially offset by improved product mix in the region due to new branded products launched within the last five years as well as positive pricing actions.
Read it in 10-K Feb 28, 2025 at sec.govopen_in_new
RemovedMD&A
Other charges (income) is primarily comprised of $76.8 million in exit charges related to our decision to cease operations and business in Russia. Additional charges of $42.4 million relate primarily to environmental charges, which were impacted by higher inflation rates.
Read it in 10-K Feb 28, 2025 at sec.govopen_in_new
RemovedMD&A
The charge for 2023 was $18.2 million compared to $8.6 million in 2022. Higher interest rates during the period resulted in an increase to interest costs for pension and other postretirement benefits.
Read it in 10-K Feb 28, 2025 at sec.govopen_in_new
RemovedMD&A
(10)Interest payments were consistent in 2024 as compared to 2023. Interest payments were higher during 2023 compared to 2022 largely due to the timing of interest payments as well as higher commercial paper rates.
Read it in 10-K Feb 28, 2025 at sec.govopen_in_new
RemovedMD&A
(12)Represents payments for legal and professional fees associated with integrating the DuPont Crop Protection Business. The integration is complete and the 2022 payments are associated with settlement of final amounts payable.
Read it in 10-K Feb 28, 2025 at sec.govopen_in_new
RemovedMD&A
Cash required for 2022 is primarily related to capital expenditures needed for increased capacity, as well the consideration paid for the BioPhero acquisition. Capital expenditures in 2022 increased due to spending directed towards capacity expansion. This usage of cash was offset by the proceeds received on the disposition of land on a previously shutdown manufacturing facility.
Read it in 10-K Feb 28, 2025 at sec.govopen_in_new
RemovedMD&A
We expect 2025 cash provided (required) by operating activities of continuing operations to be in the range of approximately $400 million to $570 million. We expect 2025 free cash flow (Non-GAAP) to fall within a range of approximately $200 million and $400 million. The expected decrease in both measures at the midpoint is primarily the result of our expectation of a normalization of working capital after the pronounced correction in 2024.
Read it in 10-K Feb 28, 2025 at sec.govopen_in_new
RewordedMD&A
(in Millions, except per share amounts) Year Ended December 31, 2025 2024 2023 2022 Net income (loss) attributable to FMC stockholders (GAAP) $ (2,238.9) $ 341.1 $ 1,321.5 $ 736.5 Corporate special charges (income), pre-tax (1) 1,794.4 238.0 256.3 101.7 India held for sale business (2) 521.7 — — Income tax expense (benefit) on Corporate special charges (income) (2) (3) (158.1) (37.1) (32.8) 1.5 Corporate special charges (income), net of income taxes $ 2,158.0 $ 200.9 $ 223.5 $ 103.2 Adjustment for noncontrolling interest, net of tax on Corporate special charges (income) — — (1.6) 6.8 Discontinued operations attributable to FMC Stockholders, net of income taxes 36.6 61.8 98.5 97.2 Non-GAAP non-GAAP tax adjustments (3) (4) 416.3 (167.5) (1,167.4) (5.3) Adjusted after-tax earnings from continuing operations attributable to FMC stockholders (Non-GAAP) (non-GAAP) $ 372.0 $ 436.3 $ 474.5 $ 938.4 Diluted earnings per common share (GAAP) $ (17.88) $ 2.72 $ 10.53 $ 5.81 Corporate special charges (income), pre-tax per diluted share 14.33 1.90 2.05 0.81 India held for sale business 4.16 — — Income tax expense (benefit) on Corporate special charges (income) per diluted share (1.26) (0.30) (0.26) 0.01 Corporate special charges (income), net of income taxes per diluted share $ 4.32 17.23 $ 12.32 1.60 $ 6.63 1.79 Adjustment for noncontrolling interest, net of tax on Corporate special charges (income) per diluted share — — (0.02) 0.05 Discontinued operations attributable to FMC stockholders, net of income taxes per diluted share 0.29 0.49 0.78 0.77 Tax adjustments per diluted share 3.32 (1.33) (9.30) (0.04) Adjusted after-tax earnings from continuing operations attributable to FMC stockholders per diluted share (Non-GAAP) (non-GAAP) $ 2.96 $ 3.48 $ 3.78 $ 7.41 Average number of shares outstanding used in the adjusted after-tax earnings from continuing operations per diluted share computations (5) 125.6 125.4 125.5 126.7
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
RewordedMD&A
(in Millions) Year Ended December 31, 2025 2024 2023 2022 Revenue (GAAP) $ 3,467.4 $ 4,246.1 $ 4,486.8 $ 5,802.3 Costs and Expenses expenses Costs of sales and services 2,184.4 2,597.2 2,655.8 3,475.5 Gross Margin margin $ 1,283.0 $ 1,648.9 $ 1,831.0 $ 2,326.8 Selling, general and administrative expenses 684.9 644.6 734.3 775.2 Research and development expenses 266.1 278.0 328.8 314.2 Restructuring and other charges (income) 1,960.3 219.8 212.3 93.1 Total costs and expenses $ 5,095.7 $ 3,739.6 $ 3,931.2 $ 4,658.0 Income from continuing operations before non-operating pension pension, postretirement and postretirement other charges (income), interest expense, net and income taxes (1) taxes(1) $ (1,628.3) $ 506.5 $ 555.6 $ 1,144.3 Non-operating pension pension, postretirement and postretirement other charges (income) 18.7 18.2 18.2 8.6 Interest expense, net 239.6 235.8 237.2 151.8 Income (loss) from continuing operations before income taxes $ (1,886.6) $ 252.5 $ 300.2 $ 983.9 Provision (benefit) for income taxes 314.2 (150.9) (1,119.3) 145.2 Income (loss) from continuing operations $ (2,200.8) $ 403.4 $ 1,419.5 $ 838.7 Discontinued operations, net of income taxes (36.6) (61.8) (98.5) (97.2) Net income (loss) (GAAP) $ (2,237.4) $ 341.6 $ 1,321.0 $ 741.5 Adjustments to arrive at Adjusted EBITDA (Non-GAAP): (non-GAAP):
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
RewordedMD&A
Gross Excluding the impact of the one-time commercial actions, our gross margin as a percent of revenue of 38.8 percent decreased was 41 percent, which increased compared to a gross margin percentage of 40.8 39 percent in the prior year period driven as a result of continued cost improvement partially offset by higher unabsorbed fixed costs lower pricing during the period as well as registration removals. period.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
RewordedMD&A
Twelve Months Ended December 31, 2024 2025 Net income (loss) attributable to FMC stockholders (GAAP) $ 341.1 (2,238.9) Interest expense, net, net of income taxes 210.1 208.4 Corporate special charges (income) 238.0 1,794.4 India held for sale business 521.7 Income tax expense (benefit) on Corporate special charges (income) (37.1) (158.1) Discontinued operations attributable to FMC stockholders, net of income taxes 61.8 36.6 Tax adjustments (167.5) 416.3 ROIC numerator (Non-GAAP) (non-GAAP) $ 646.4 580.4 December 31, 2025 December 31, 2024 December 31, 2023 Total debt $ 3,365.3 $3,957.6 4,074.9 $3,365.3 Total FMC stockholders’ equity 2,071.5 4,487.5 4,410.9 Total debt and FMC stockholders' equity (GAAP) $ 7,852.8 $8,368.5 6,146.4 $7,852.8 ROIC denominator (2 yr average total debt and FMC stockholders' equity) $ 8,110.7 6,999.6 ROIC (using Net income (loss) attributable to FMC stockholders (GAAP) as numerator) 4.21 (31.99) % Adjusted ROIC (using Non-GAAP non-GAAP numerator) 7.97 8.29 %
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
RewordedMD&A
Year Ended December 31, 2025 2024 2023 2022 (in Millions) Income (Expense) Tax Provision (Benefit) Effective Tax Rate Income (Expense) Tax Provision (Benefit) Effective Tax Rate Income (Expense) Tax Provision (Benefit) Effective Tax Rate GAAP - Continuing operations $ (1,886.6) $ 314.2 (16.7)% $ 252.5 $ (150.9) (59.8)% $ 300.2 $ (1,119.3) (372.9)% $ 983.9 $ 145.2 14.8% Corporate special charges (income) 2,316.1 158.1 238.0 37.1 256.3 32.8 101.7 (1.5) Revisions to valuation allowances of historical deferred tax assets (1) — (45.3) — 1.6 — 223.5 — — Net impact of Switzerland tax incentives (1) — (334.7) — 153.9 — 830.8 — — Foreign currency and other discrete items (1) — (36.3) — 12.0 — 113.1 — 5.3 Non-GAAP non-GAAP - Continuing operations $ 429.5 $ 56.0 13.0% $ 490.5 $ 53.7 10.9% $ 556.5 $ 80.9 14.5% $ 1,085.6 $ 149.0 13.7%
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
RewordedMD&A
Restructuring and other charges (income) (3) $ 1,775.7 $ 219.8 $ 238.1 $ 93.1 Non-operating pension pension, postretirement and postretirement other charges (income) (4) (income)(4) 18.7 18.2 18.2 8.6 India held for sale business (5) 521.7 — — Discontinued operations, net of income taxes 36.6 61.8 98.5 97.2 Interest expense, net 239.6 235.8 237.2 151.8 Depreciation and amortization 173.6 176.3 184.3 169.4 Provision (benefit) for income taxes 314.2 (150.9) (1,119.3) 145.2 Adjusted EBITDA (Non-GAAP) (non-GAAP) (2) $ 842.7 $ 902.6 $ 978.0 $ 1,406.8
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
RewordedMD&A
In connection with Project Focus, Foundation, the Company expects to incur pre-tax restructuring charges over the life of the program in the range of approximately $375 $560 million to $425 $635 million, inclusive of charges incurred during 2024 as well as $45.5 million of charges incurred which is subject to future changes, in 2023. connection with these efforts.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
RewordedMD&A
The majority of the minimum obligations under these contracts are take-or-pay commitments over the life of the contract and not a year by year take-or-pay, and as As such, the obligations related to these types of contacts are presented considered payable in the earliest period in which the minimum obligation could be payable due under these types of contracts.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
RewordedMD&A
The majority of the minimum obligations under these contracts are take-or-pay commitments over the life of the contract and not a year by year take-or-pay, and as such, the obligations related to these types of contacts are presented in the earliest period in which the minimum obligation could be payable under these types of contracts. take-or-pay.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
RewordedMD&A
The change in cash flows related to trade receivables in 2024 2025 was driven by lower revenue year over year as well as timing of collections, due in part, to sales growth during the second half of the year compared to the same period in 2023. collections.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
RewordedMD&A
On a regional basis, sales in Latin America decreased by 1 percent, sales in North America decreased 3 percent, sales in Europe, Middle East and Africa increased by 4 percent, sales in Latin America decreased by 7 3 percent, and sales in Asia North America decreased 14 6 percent.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
RewordedMD&A
Revenue of $4,246.1 $3,467.4 million decreased $240.7 $778.7 million, or approximately 5 18 percent versus the prior year period. period primarily driven by revenue charges in India due to one-time commercial actions to prepare the India business for sale.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
Quiet changesMD&A
Additionally, timing of collection is impacted as amounts for all both periods include carry-over balances remaining to be collected in Latin America, where collection periods are measured in months rather than weeks.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new